Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.34 |
| ▸ | RAB9A | P51151 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13086734 | 0.82 | NPC1 (0.36) | NPC1RAB9ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL26859104 | 0.81 | SMN1; SMN2 (0.53) | NPC1RAB9ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL25097484 | 0.80 | HDAC6 (0.35) | NPC1RAB9ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL24869559 | 0.79 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL25680999 | 0.77 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL18611835 | 0.74 | BRAF (0.36) | NPC1RAB9ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL21765495 | 0.74 | KDM4E (0.34) | NPC1RAB9ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL21789412 | 0.72 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL23571997 | 0.69 | LMNA (0.32) | NPC1RAB9ASMN1; SMN2LMNAKDM4E | |
| SCHEMBL13086441 | 0.68 | DGAT1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | NPC1 245/4885RAB9A 2435/4885SMN1; SMN2 2037/4885 |
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | CFD, CFH, TFPI | NPC1 477/4885RAB9A 1876/4885SMN1; SMN2 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.